Therapeutic insulins and their large-scale manufacture

Aventis (2003) Aventis 2003 annual report. Available at http://www.aventis.com Banting F, Best C (1922) The internal secretions of the pancreas. J Lab Clin Med 7:251–266 Bliss M (1993) The history of insulin. Diabetes Care 16(3):4–7 Blundell T, Dodson G, Hodgkin D, Mercola D (1972) Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Prot Chem 26:279–402 Brange J, Ribel J, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris K, Norris L, Snel L, Sorensen AR, Voigt HO (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679–682 Brange J, Owens DR, Kang S, Volund A (1990) Monomeric insulins and their experimental and clinical implications. Diabetes Care 13(9):923–954 Carino G, Mathiowitz E (1999) Oral insulin delivery. Adv Drug Del Rev 35:249–257 Cefalu WT (2004) Concepts, strategies and feasibility of noninvasive insulin delivery. Diabetes Care 27(1):239–246 Chance R, Frank B (1993) Research, development production and safety of biosynthetic human insulin. Diabetes Care 16(3):133–142 Chance R, Glazer N, Wishner K (1999) Insulin Lispro (Humalog). In: Walsh G, Murphy B (eds) Biopharmaceuticals, an industrial perspective. Kluwer, Dordrecht pp 149–172 Ciszak E, Beals M, Frank BH (1995) Role of C-terminal B chain residues in insulin assembly: the structure of hexameric LysB28 ProB29 human insulin. Structure 3:615–622 Clement S, Dandona P, Still JG, Kosutic G (2004) Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism 53(1):54–58 Efrat S (2004) Generation of insulin producing cells from stem cells for cell replacement therapy of type 1 diabetes. Isr Med Assoc J 6(5):265–267 Frank B (1981) The production of human proinsulin and its transformation to human insulin and C peptide. In: Rich D, Gross E (eds) Proceedings of the seventh American peptide symposium on peptidases: synthesis-structure-function. Pierce Chemical, Rockford, USA, pp 729–738 Frank B (1991) Manupilation of the position of proline in the B chain produced monomeric insulins. Diabetes 40[Suppl 1]:423A Frank B, Baker J, Bakaysa D (1995) Lys B28 Pro B29 human insulin (insulin lispro): solution properties of a rapid acting insulin. Diabetologia 38[Suppl 1]:A189 Galloway JA, Chance RE (1994) Improving insulin therapy: achievements and challenges. Horm Metab Res 26(12):591–598 Generex (2004) Oralin product information. Available at http://www.generex.com Ghilzai NM (2003) New developments in insulin delivery. Drug Dev Ind Pharm 29(3):253–265 Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Markussen J, Kurtzhals P (2004) The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 21(8):1498–1504 Heise T, Nosek L, Ronn B, Endhal L, Heinemann L, Kapitza C (2004) Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53(6):1614–1620 Hinchcliffe M, Illum L (1999) Intranasal insulin delivery and therapy. Adv Drug Del Rev 35:199–234 Homandberg GA, Mattis J, Llaskowski M (1978) Synthesis of peptide bonds by proteinases. Addition of organic solvents shifts peptide bond equilibria towards synthesis. Biochemistry 17:5220–5227 Kang S, Owens DR, Vora JP, Brange J (1990) Comparison of insulin analog B9ASPB27GLU and soluble human insulin in insulin-treated diabetics. Lancet 335:303–306 Kang S, Creagh F, Peters J, Brange J, Volund A, Owens D (1991) Comparison of subcutaneous soluble human insulin and insulin analogues on meal-related plasma glucose excursions in type-1 diabetic subjects. Diabetes Care 14:571–577 Kapitza C, Hompesch M, Scharling B, Heise T, (2004) Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol Ther 6(4):466–472 Kjeldsen T (2000) Yeast secretory expression of insulin precursors. Appl Microbiol Biotechnol 54:277–286 Kjeldsen T, Ludvigsen S, Diers I, Balschmidt P, Sorensen A, Kaarsholm N (2002) Engineering-enhanced protein secretory expression in yeast with application to insulin. J Biol Chem 277(21):18245–18248 Kost J, Langer R (1991) Responsive polymeric delivery systems. Adv Drug Del Rev 6:19–50 Kurtzhals P, Havelund S, Jonassen S, Markussen J (1997) Effect of fatty acids and selected drugs on the albumin binding of a long acting, acylated insulin analogue. J Pharm Sci 86(12):1365–1368 Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T, (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49(6):999–1005 Lee MK, Bae YH (2000) Cell transplantation for endocrine disorders. Adv Drug Del Rev 42:103–120 Levene F, Leibowitz G (1999) Towards gene therapy of diabetes mellitus. Mol Med Today 5:165–171 Lilly (2003) Lilly 2003 annual report. Available at http://www.lilly.com Markussen J (1980) Process for preparing insulin esters. United Kingdom patent application GB 2069502 A Markussen J, Jorgensen K, Thim L, Damgaard U, Sorensen E, Dodson G, Chawdhury F (1981) Human monocomponent insulin: chemistry and characteristics of human insulin. Diabetologia 21:302 Markussen J, Damgaard U, Diers I, Fiil N, Hansen M, Lassen P, Norris F, Norris P, Schou O, Snel L, Thim L, Voigt H (1986) Biosynthesis of human insulin in yeast via single chain precursors. Diabetologia 29:568A–569A Morihara K, Oka T, Tsuzukih H (1979) Semi synthesis of human insulin by trypsin-catalyzed replacement of Ala-B30 by Thr in porcine insulin. Nature 280:412–413 Nett PC, Sollinger HW, Alam T (2003) Hepatic insulin gene therapy in insulin-dependent diabetes mellitus. Am J Transplant 3(10):1197–1203 Nicol S, Smith M (1960) Amino acid sequence of human insulin. Nature 187:483–485 Novo (2003) Novo nordisk 2003 annual report. Available at http://www.novonordisk.com Owens DR, Vora JP, Dolben J (1991) Human insulin and beyond: semisynthesis and recombinant DNA technology reviewed. In: Pickup JC (ed) Biotechnology of insulin therapy. Blackwell, Oxford, pp 24–41 Owens DR, Zinman B, Bolli G (2001) Insulins today and beyond. Lancet 358:739–746 Owens DR, Zinman B, Bolli G (2003). Alternative routes of insulin delivery. Diabet Med 20(11):886–898 Patton J (1996) Mechanisms of macromolecule absorption by the lungs. Adv Drug Del Rev 19:3–36 Patton J, Bukar J, Nagarajan S (1999) Inhaled insulin. Adv Drug Del Rev 35:235–247 Peck AB, Ramiya V (2004) In vitro generation of surrogate islets from adult stem cells. Transpl Immunol 12(3–4):259–272 Pillai O, Panchagnula R (2001) Insulin therapies—past, present and future. Drug Discov Today 20(6):1056–1061 Roche E, Sepulcre MP, Ensenat-Waser R, Maestre I, Reig JA, Soria B (2003) Bio-engineering insulin-secreting cells from embryonic stem cells: a review of progress. Med Biol Eng Comput 41(4):384–391 Scott D (1934) Crystalline insulin. Biochem J 28(II):1592–1602 Sieber P, Kamber B, Hartmann A, Johl A, Riniker B, Rittel W (1974) Total synthese von human insulin unter gezielter bildung der disulfid bindungen. Helv Chim Acta 57:2617–2621 Steil GM, Panteleon AE, Rebrin K (2004) Cloosed-loop insulin delivery—the path to physiological glucose control. Adv Drug Del Rev 56(2):125–144 Sutcliffe J, Duin N (1992) A history of medicine. Barnes and Noble, USA, pp 104–105 Thim L, Hansen MT, Norris K, Hoegh I, Boel E, Forstrom J, Ammerer G, Fiil NP (1986) Secretion and processing of insulin precursors in yeast. PNAS 83:6766–6770 Vora JP, Owens DR, Dolben J, Atiea TA, Dean JD, Kang S, Burch A, Brange J (1988) Recombinant DNA derived monomeric insulin analogue. Comparison with soluble human insulin in normal subjects. Br Med J 297:1236–1239 Walsh G (1998) Biopharmaceuticals: biochemistry and biotechnology. Wiley, Chichester WHO (2004) Diabetes action report. Available at http://www.who.int Yoon JW, Jun HS (2002) Recent advances in gene therapy for type 1 diabetes. Trends Mol Med 8(2):62–68